The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT00589134
Collaborator
(none)
26
1
1
47
0.6

Study Details

Study Description

Brief Summary

Women are at greater risk for exercise-induced hyponatremia (low blood sodium concentration) and this risk has been attributed to their lower body weight and size, excess water ingestion and longer racing times relative to men. While these factors contribute to the greater incidence of hyponatremia in women, it is likely that their greater levels of estradiol in plasma and/or tissue also play a role in increasing the risk of hyponatremia in women. More importantly, estradiol may also leave women more susceptible to the extreme consequences of hyponatremia (i.e. brain damage, death). Hyponatremia is generally attributed to inappropriately elevated levels of the hormone arginine vasopressin (AVP). AVP is the most important hormone controlling water retention in the kidney. Earlier studies in our laboratory have demonstrated that estradiol lowers the threshold for thirst sensation and AVP release during exercise. The purpose of these studies is to test the hypotheses that in women with a history of hyponatremia, estradiol lowers the thresholds for thirst and AVP release, leading to greater fluid retention, lower blood sodium concentration during endurance exercise in the heat. However, we further hypothesize that progesterone administration along with estradiol administration will attenuate the effect of estradiol on the regulation of thirst and AVP, normalize fluid retention, and serum sodium concentration during endurance exercise in the heat. In women without a history of hyponatremia, we expect that estradiol administration will lower the thresholds for thirst and AVP release, but will not increase fluid retention or reduce blood sodium concentration during endurance exercise in the heat. We hypothesize that progesterone administration along with estradiol administration will attenuate the effect of estradiol on thirst and AVP, but have no effect on fluid retention or serum sodium concentration during endurance exercise in the heat. To test these hypotheses, women will perform endurance exercise in the heat under three hormonal conditions: 1) during Gonadotropin-releasing hormone (GnRH) antagonist alone--which will suppress estradiol and progesterone; 2) during GnRH antagonist+estradiol; and 3) during GnRH antagonist+estradiol+ progesterone. During exercise, fluid will be replaced with either water or a carbohydrate-electrolyte beverage (random assignment).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Gatorade Endurance Formula
  • Other: ganirelix acetate
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration
Study Start Date :
Jan 1, 2006
Actual Primary Completion Date :
Dec 1, 2009
Actual Study Completion Date :
Dec 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

type of beverage

Dietary Supplement: Gatorade Endurance Formula
carbohydrate electrolyte beverage

Other: ganirelix acetate
GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
Other Names:
  • Antagon
  • Outcome Measures

    Primary Outcome Measures

    1. osmotic regulation of AVP [3 years]

    Secondary Outcome Measures

    1. temperature responses [3 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 35 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • healthy volunteers (18-35 yrs) with and without previous exercise induced hyponatremia
    Exclusion Criteria:
    • conditions that would preclude safe exercise or safe use of hormones

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 John B. Pierce Laboratory New Haven Connecticut United States 06519

    Sponsors and Collaborators

    • Yale University

    Investigators

    • Principal Investigator: Nina Stachenfeld, PhD, John B. Pierce Laboratory

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00589134
    Other Study ID Numbers:
    • 0508000538
    First Posted:
    Jan 9, 2008
    Last Update Posted:
    Mar 30, 2020
    Last Verified:
    Jul 1, 2010
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 30, 2020